Asthma Drugs Market (By Medication: Quick Relief Medications, Long-term Control Medications, Others; By Mode of Administration: Tablets and Capsules, Liquids, Inhalers, Injections, and Sprays and Powders; By Source: Environmental, Generic; By Organization Type: Public, Private; By Application: Pediatric, Adults, Adolescent) - Global Market Size, Share, Growth, Trends Analysis, Regional Outlook and Forecasts 2021 - 2030

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Asthma Drugs Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Asthma Drugs Market

5.1. Covid-19: Asthma Drugs Industry Impact
5.2. Asthma Drugs Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Asthma Drugs Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Asthma Drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Asthma Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of asthma, along with increase in ageing population
6.1.1.2. Increase in pipeline products growth in initiatives implemented by the government and non-government associations for rise in health awareness
6.1.2. Market Restraints
6.1.2.1. Stringent government regulatory requirement for the approval of asthma drugs
6.1.3. Market Opportunities
6.1.3.1. Major companies are focusing on broadening their product portfolio

Chapter 7. Global Asthma Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Asthma Drugs Market Revenue by Market Players (2017 - 2020)
7.1.1.2. Asthma Drugs Market Revenue Market Share by Market Players (2017 - 2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Process Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Asthma Drugs Market, By Medication Type

8.1. Asthma Drugs Market, by Medication Type, 2017-2030
8.1.1. Quick Relief Medications
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Long-term Control Medications
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Asthma Drugs Market, By Mode of Administration

9.1. Asthma Drugs Market, by Mode of Administration, 2017-2030
9.1.1. Tablets and Capsules
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Liquids
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Inhalers
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Injections
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Sprays and Powders
9.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Asthma Drugs Market, By Source

10.1. Asthma Drugs Market, by Source, 2017-2030
10.1.1. Environmental
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Generic
10.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Asthma Drugs Market, By Organization Type

11.1. Asthma Drugs Market, by Application, 2017-2030
11.1.1. Public
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Private
11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Asthma Drugs Market, By Application

12.1. Asthma Drugs Market, by Application, 2017-2030
12.1.1. Pediatric
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Adults
12.1.2.1. Market Revenue and Forecast (2017-2030)
12.1.3. Adolescent
12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Asthma Drugs Market, Regional Estimates and Trend Forecast

13.1. North America
13.1.1. Market Revenue Forecast by Medication Type (2017-2030)
13.1.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.1.3. Market Revenue Forecast by Source (2017-2030)
13.1.4. Market Revenue Forecast by Organization Type (2017-2030)
13.1.5. Market Revenue Forecast by Application (2017-2030)
13.1.6. U.S
13.1.6.1. Market Revenue Forecast (2017-2030)
13.1.7. Canada
13.1.7.1. Market Revenue Forecast (2017-2030)
13.2. Europe
13.2.1. Market Revenue Forecast by Medication Type (2017-2030)
13.2.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.2.3. Market Revenue Forecast by Source (2017-2030)
13.2.4. Market Revenue Forecast by Organization Type (2017-2030)
13.2.5. Market Revenue Forecast by Application (2017-2030)
13.2.6. UK
13.2.6.1. Market Revenue Forecast (2017-2030)
13.2.7. Germany
13.2.7.1. Market Revenue Forecast (2017-2030)
13.2.8. France
13.2.8.1. Market Revenue Forecast (2017-2030)
13.2.9. Rest of EU
13.2.9.1. Market Revenue Forecast (2017-2030)
13.3. Asia Pacific (APAC)
13.3.1. Market Revenue Forecast by Medication Type (2017-2030)
13.3.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.3.3. Market Revenue Forecast by Source (2017-2030)
13.3.4. Market Revenue Forecast by Organization Type (2017-2030)
13.3.5. Market Revenue Forecast by Application (2017-2030)
13.3.6. China
13.3.6.1. Market Revenue Forecast (2017-2030)
13.3.7. India
13.3.7.1. Market Revenue Forecast (2017-2030)
13.3.8. Japan
13.3.8.1. Market Revenue Forecast (2017-2030)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue Forecast (2017-2030)
13.4. LATAM
13.4.1. Market Revenue Forecast by Medication Type (2017-2030)
13.4.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.4.3. Market Revenue Forecast by Source (2017-2030)
13.4.4. Market Revenue Forecast by Organization Type (2017-2030)
13.4.5. Market Revenue Forecast by Application (2017-2030)
13.4.6. Brazil
13.4.6.1. Market Revenue Forecast (2017-2030)
13.4.7. Rest of LATAM
13.4.7.1. Market Revenue Forecast (2017-2030)
13.5. Middle East and Africa (MEA)
13.5.1. Market Revenue Forecast by Medication Type (2017-2030)
13.5.2. Market Revenue Forecast by Mode of Administration (2017-2030)
13.5.3. Market Revenue Forecast by Source (2017-2030)
13.5.4. Market Revenue Forecast by Organization Type (2017-2030)
13.5.5. Market Revenue Forecast by Application (2017-2030)
13.5.6. GCC
13.5.6.1. Market Revenue Forecast (2017-2030)
13.5.7. North Africa
13.5.7.1. Market Revenue Forecast (2017-2030)
13.5.8. South Africa
13.5.8.1. Market Revenue Forecast (2017-2030)
13.5.9. Rest of MEA
13.5.9.1. Market Revenue Forecast (2017-2030)

Chapter 14. Company Profiles

14.1. Pfizer
14.1.1. Company Overview, Business Information, Regional Presence
14.1.2. Product Portfolio Analysis
14.1.2.1. Product Details, Specification, Product Type
14.1.3. Revenue, Price, and Gross Margin (2017-2020)
14.1.4. Recent Developments and Strategies
14.2. GlaxoSmithKline
14.2.1. Company Overview, Business Information, Regional Presence
14.2.2. Product Portfolio Analysis
14.2.2.1. Product Details, Specification, Product Type
14.2.3. Revenue, Price, and Gross Margin (2017-2020)
14.2.4. Recent Developments and Strategies
14.3. Novartis
14.3.1. Company Overview, Business Information, Regional Presence
14.3.2. Product Portfolio Analysis
14.3.2.1. Product Details, Specification, Product Type
14.3.3. Revenue, Price, and Gross Margin (2017-2020)
14.3.4. Recent Developments and Strategies
14.4. Merck
14.4.1. Company Overview, Business Information, Regional Presence
14.4.2. Product Portfolio Analysis
14.4.2.1. Product Details, Specification, Product Type
14.4.3. Revenue, Price, and Gross Margin (2017-2020)
14.4.4. Recent Developments and Strategies
14.5. Boehringer Ingelheim
14.5.1. Company Overview, Business Information, Regional Presence
14.5.2. Product Portfolio Analysis
14.5.2.1. Product Details, Specification, Product Type
14.5.3. Revenue, Price, and Gross Margin (2017-2020)
14.5.4. Recent Developments and Strategies
14.6. AstraZeneca
14.6.1. Company Overview, Business Information, Regional Presence
14.6.2. Product Portfolio Analysis
14.6.2.1. Product Details, Specification, Product Type
14.6.3. Revenue, Price, and Gross Margin (2017-2020)
14.6.4. Recent Developments and Strategies
14.7. Roche
14.7.1. Company Overview, Business Information, Regional Presence
14.7.2. Product Portfolio Analysis
14.7.2.1. Product Details, Specification, Product Type
14.7.3. Revenue, Price, and Gross Margin (2017-2020)
14.7.4. Recent Developments and Strategies
14.8. Teva Pharmaceutical
14.8.1. Company Overview, Business Information, Regional Presence
14.8.2. Product Portfolio Analysis
14.8.2.1. Product Details, Specification, Product Type
14.8.3. Revenue, Price, and Gross Margin (2017-2020)
14.8.4. Recent Developments and Strategies
14.9. Vectura Group
14.9.1. Company Overview, Business Information, Regional Presence
14.9.2. Product Portfolio Analysis
14.9.2.1. Product Details, Specification, Product Type
14.9.3. Revenue, Price, and Gross Margin (2017-2020)
14.9.4. Recent Developments and Strategies

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms

Request for Customize Reports
Precedence offers custom market research services that help clients to get information on their business scenario required.

PROCEED TO BUY

   USD 4999
   USD 7999

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence client

Get a Sample
Address: Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com